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Abstract
Background: The challenge of gene expression studies is to reliably quantify levels of transcripts, but this is hindered by a
number of factors including sample availability, handling and storage. The PAXgene™ Blood RNA System includes a stabilizing
additive in a plastic evacuated tube, but requires 2.5 mL blood, which makes routine implementation impractical for paediatric
use.
The aim of this study was to modify the PAXgene™ Blood RNA System kit protocol for application to small, sick chidren,
without compromising RNA integrity, and subsequently to perform quantitative analysis of ICAM and interleukin-6 gene
expression.
Aliquots of 0.86 mL PAXgene™ reagent were put into microtubes and 0.3 mL whole blood added to maintain the same
recommended proportions as in the PAXgene™ evacuated tube system. RNA quality was assessed using the Agilent
BioAnalyser 2100 and an in-house TaqMan™ assay which measures GAPDH transcript integrity by determining 3' to 5' ratios.
qPCR analysis was performed on an additional panel of 7 housekeeping genes. Three reference genes (HPRT1, YWHAZ and
GAPDH) were identified using the GeNORM algorithm, which were subsequently used to normalising target gene expression
levels. ICAM-1 and IL-6 gene expression were measured in 87 Malawian children with invasive pneumococcal disease.
Results: Total RNA yield was between 1,114 and 2,950 ng and the BioAnalyser 2100 demonstrated discernible 18s and 28s
bands. The cycle threshold values obtained for the seven housekeeping genes were between 15 and 30 and showed good
consistency. Median relative ICAM and IL-6 gene expression were significantly reduced in non-survivors compared to survivors
(ICAM: 3.56 vs 4.41, p = 0.04, and IL-6: 2.16 vs 6.73, p = 0.02).
Conclusion: We have successfully modified the PAXgene™ blood collection system for use in small children and demonstrated
preservation of RNA integrity and successful quantitative real-time PCR analysis.
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The main challenge of quantitative gene expression stud-
ies is to extract sufficient usable messenger ribonucleic
acid (mRNA), to avoid degradation and permit analysis
for calculation of exact numbers of transcript. The proc-
esses of sample collection, transport, processing and stor-
age may result in significant degradation of mRNA [1].
Because of the lability of mRNA in clinical samples, it is
essential that the integrity of the mRNA is assessed before
proceeding with downstream applications such as reverse
transcription real-time quantitative polymerase chain
reaction (RTqPCR) and micro-array analyses. Both tech-
niques are highly sensitive and rely on meticulous and
consistent sample processing [2,3]. The correct interpreta-
tion of transcript abundance requires stabilisation of the
transcriptome at the point of sample collection, through
storage and transport, in order for gene expression to be
detected in a reproducible manner [4].
The PAXgene™ Blood RNA System (PreAnalytiX, QIAGEN,
Germany), includes a stabilizing additive in an evacuated
blood collection tube called the PAXgene™ Blood RNA
Tube, and also sample processing reagents in the PAX-
gene™ Blood RNA Kit. The additive in the PAXgene™ tube
reduces RNA degradation of 2.5 mL of blood in the evac-
uated tube, and furthermore, the RNA in whole blood has
been shown to be stable at room temperature for 5 days,
following storage for up to 12 months at -20°C and -
80°C, and also after repeated freeze-thaw cycles [5].
Recent studies have shown that RNA can be detected and
quantified in peripheral blood collected into PAXgene™
collection tubes, and has allowed comparison of RNA lev-
els between patients with diabetic retinopathy [6], thyroid
cancer [7] and healthy controls.
The PAXgene™ tube reagents have been used to assess
inflammatory responses in vivo using 2.5 mL of whole
blood and in vitro using 200 µL of heparinised blood [3].
An assay using branched DNA has been described to
quantitatively measure mRNA expression from small
blood volumes, but this method did not utilise the PAX-
gene™ Blood RNA system [8].
Children with pneumococcal disease in developing coun-
tries such as Malawi often present late, and are critically ill
by the time they reach hospital. It is difficult to collect 2.5
mls of blood from such children in the evacuated PAX-
gene™ Blood RNA Tube using the suggested protocol, and
therefore we sought to optimise the protocol for use in
small, sick children by employing smaller blood volumes
in paediatric microtubes, and to subsequently use the
RNA for the quantification of cytokine and mediator
responses to invasive pneumococcal disease.
Intracellular adhesion molecules (ICAMs), vascular cell
adhesion molecules (VCAMs), β2 integrins (CD11a/CD18
and CD11b/CD18), P-selectin and E-selectin are involved
in the adhesion of circulating leucocytes to endothelial
cells. P-selectin and ICAM-1 (but not VCAM-1) are up-reg-
ulated in experimental pneumococcal meningitis [9].
Pneumolysin, a major virulence factor for Streptococcus
pneumoniae increases ICAM-1 mRNA [10]. Fucoidin, an L-
selectin blocker profoundly reduces leucocyte rolling (a
precondition for leucocyte adhesion to vascular endothe-
lium), pleocytosis and increased CSF protein levels in
experimental pneumococcal meningitis, thereby reducing
leucocyte dependent damage in bacterial meningitis [11].
Interleukin-6 (IL-6) production is a marker of sepsis-
related mortality and poor outcome in models of pneu-
mococcal disease [12] and increased IL-6 production has
been shown in the lungs of pneumococcal-infected mice
[13]. On the basis of existing knowledge of the biological
function of the ICAM and IL-6 genes in the host response
to pneumococcal infection, we conducted a pilot study to
quantify ICAM and IL-6 gene expression in Malawian chil-
dren presenting with invasive pneumococcal disease.
Before proceeding with RT qPCR analysis, we validated
the scaled-down method by assessing mRNA integrity
using an in-house assay that measures three regions of the
GAPDH transcript.
Results
Whole blood extraction from healthy volunteers
Whole venous blood was collected from healthy volun-
teers and either 2.5, 1.0 or 0.3 mL added to the Paxgene
blood RNA reagent in the same ratio as the manufacturers
guidelines. The total RNA yield from 2.5, 1.0 and 0.3 mL
of whole blood was 4.5 – 11.6 µg, 5.1 – 8.3 µg and 1.6 to
5.0 µg respectively. With optical density ratios (260/280)
of 1.97–2.14. Figure 1 shows Agilent 2100 Bioanalyser
traces for the total RNA extracted from the different vol-
umes of whole blood. Panel A shows the full scale (2.5
mL) blood RNA extraction, panels B and C show total
RNA from the low volume extractions, for comparison
panel D shows the trace for Stratagene Universal RNA. The
18s and 28s RNA peaks can be seen at approximately 42
and 49 seconds respectively. Both the 2.5 mL and 1.0 mL
extractions were loaded on to Eukaryote total RNA Nano
chips whereas the 0.3 mL extractions were loaded on to
Eukaryote total RNA Pico chips. The Bioanalyser software
generates RNA Integrity Numbers (RIN) for each sample
giving an estimate of the RNA integrity. Total RNA
extracted from 0.3 – 2.5 mL had a RIN of between 8.2 and
9.6. RNA was reverse transcribed and assayed for a panel
of reference genes to ensure expression profiles were
maintained across all volumes extracted.Page 2 of 8
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pneumococcal disease and controls
Whole venous blood samples were collected from 87 chil-
dren with confirmed invasive pneumococcal disease. A
total of 48 children (55%) were male, and the age range
was 0.17 to 13 years, median age 3.25 years. There were 25
(28.7%) non-survivors. Of the children with IPD, 75 had
meningitis(86%) and 12 had pneumonia (14%).
Total RNA yield from 0.3 mL of whole blood varied
between 1.1 and 2.9 µg with 260/280 ratios of 1.91 –
2.03. Eight small volume blood samples were processed
using the method described below and amplified for the
3 GAPDH assays. Figure 2a shows that in all cases a good
signal is detected across the whole GAPDH gene, thereby
indicating that full length mRNA has been isolated. Figure
2b shows the raw Ct values obtained for the 8 samples
with a panel of 7 additional housekeeper genes. The sam-
ples show excellent consistency in the expression levels for
all the housekeeper assays further indicating that all the
RNA samples have good mRNA integrity. The RT qPCR
assays were shown to be a more sensitive method of RNA
QC analysis for samples and could be used in place of the
Bioanalyser.
The RNA yields were low but sufficient cDNA was pro-
duced to perform RT qPCR experiments to quantify ICAM
and IL-6 gene expression. Relative gene expression (2-∆∆Ct)
was significantly higher in survivors compared to non-sur-
vivors and controls (ICAM: p < 0.0005 and IL-6: p =
0.003, Kruskal Wallis). Relative gene expression was sig-
nificantly lower than in non-survivors than survivors;
ICAM: median (IQR); 3.56 (0.82 – 5.72) versus 4.41 (1.44
– 9.57), and IL-6: median (IQR); 2.16 (0.71 – 5.72) versus
6.73 (1.17 – 14.93). Relative gene expression was signifi-
cantly lower in controls than cases ICAM: 1.00 (0.54 –
1.79) versus 4.17(1.29 – 8.06) and IL-6: 0.92 (0.49 –
2.28) versus 4.32(0.81 – 13.27) (p < 0.0005 and p = 0.01
respectively) (Figure 3).
Discussion
In this study using 0.3 mL of whole blood we have modi-
fied the PAXgene™ Blood RNA System for use in small sick
children. Our results show that in all cases a near equiva-
Agilent BioAnalyser 2100 traces of total RNA samplesFigure 1
Agilent BioAnalyser 2100 traces of total RNA samples. Different volumes of peripheral blood were processed using PAXgene 
reagent as described in the text. A) Full scale 2.5 mL peripheral blood extraction B) 1.0 mL peripheral blood scaled down 
extraction C) 0.3 mL peripheral blood scaled down extraction D) Stratagene Universal RNA. The 2.5 mL and 1.0 mL extrac-
tions were run on eukaryote total RNA Nano chips and the 0.3 mL extractions and the Universal RNA shown were run on 
Pico chips. The 18s and 28s RNA peaks can be seen at approximately 42 and 48 seconds respectively.Page 3 of 8
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GAPDH gene, thereby indicating that full length mRNA
has been isolated. In turn, this result in combination with
the similar levels of expression seen for 7 reference genes
suggests that other transcripts are useable for RT qPCR
analyses. We believe that this approach to assessing tran-
script integrity will be of general utility in transcriptional
analysis. The RNA was then successfully applied for down-
stream quantitative gene expression of the ICAM-1 and IL-
6 genes, using RT qPCR.
Our data show that ICAM-1 and IL-6 expression are
increased in cases compared to healthy controls, and that
expression is also increased in survivors compared to non-
survivors with invasive pneumococcal disease. This is con-
sistent with a study by Rieckmann et al. where elevated
soluble ICAM-1 (sICAM-1) levels were seen in the cere-
brospinal fluid of patients with bacterial meningitis [14].
Increased IL-6 expression has been shown in a rat model
of pneumocococal infection [15], and IL-6 GG
homozygous patients (with increased IL-6 transcription
and production) were less likely to develop extrapulmo-
nary pneumococcal infection (as marker of impaired
clearance of bacteria) [16]. ICAM-1 plays an important
role in tight binding of leucocytes to the endothelium,
and IL-6 is required for the clearance of bacteria. Our data
would suggest that under-expression of both these media-
tors may be detrimental to the host.
The PAXgene™ Blood RNA System allows stabilisation of
the transcriptome at the point of collection, at the bed-
side, and thus facilitates the ready access of gene expres-
sion studies to the clinical research scientist. The samples
do not need to be processed immediately, and can be
stored at room temperature for up to 24 hours before
freezing or extraction, although different handling condi-
tions have been shown to contribute minimally (0.09%)
to differences in gene expression levels [4].
Previous researchers have found that the PAXgene™ Blood
RNA System produced reliable gene expression profiles
using the Affymetrix GeneChip® system, and showed
small but significant differences in gene expression
between two sample handling methods. Samples which
were freshly extracted had higher DNA contamination,
and lower total RNA yield than those which were frozen
at -20°C before extraction, but the authors do not explain
this finding [4]. In this study we have chosen a consistent
method of sample processing (incubate at room tempera-
ture for a maximum of two hours and freeze at -80°C
before extraction) to reduce variability. Another study
showed that a longer incubation time of 24 hours in PAX-
gene™ tubes before extraction produced a higher total
RNA yield than incubation times of 4 hours. This might be
another useful strategy for application to small volume
samples such as those drawn from children [17].
The method described in this study produced sufficient
mRNA for successful downstream quantitative gene
expression analysis, but did not consistently produce suf-
ficient RNA for application on a micro-array using
Affymetrix GeneChips®.
Conclusion
In summary the results presented here show a robust effi-
cient system for the collection and processing of blood
samples to allow accurate expression profiling. We have
demonstrated that 0.3 mL of whole blood can be rou-
tinely used as the basis for transcriptional profiling studies
thereby making this approach available to neonatal and
paediatric studies, but may have other clinical applica-
tions where availability of blood is limited, such as small
animal veterinary science.
Real time qPCR results obtained using small volumes of whole bloodFigure 2
Real time qPCR results obtained using small volumes of 
whole blood. Figure 2a shows the Ct values obtained when 8 
RNA extracts were assayed for 7 housekeeper genes. Figure 
2b shows the Ct values for 3 assays detecting GAPDH at 3' 
(), mid () and 5' () positions.
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Patient recruitment
Children in this study were admitted to the Queen Eliza-
beth Central Hospital, Blantyre, Malawi, and recruited
into a prospective observational study of host determi-
nants of invasive pneumococcal disease susceptibility and
severity in Malawian children, the details of which have
been described elsewhere [18]. Controls were taken from
healthy, afebrile children from the same villages as the
cases. The study protocol was approved by the College of
Medicine Research Ethics Committees, both in Blantyre,
Malawi and the Local Research Ethics Committee at the
Liverpool School of Tropical Medicine, United Kingdom.
Written informed consent was obtained from parents or
guardians before children were included into the study.
Sample collection
Peripheral whole blood (0.3 mL) from venepuncture was
dispensed into micro-tubes pre-aliquoted with PAXgene™
reagent (0.86 mL), keeping the blood:reagent ratio the
same as in the PAXgene™ Blood RNA Tubes [Qiagen]. The
sample was gently inverted and stored at -80°C within
two hours of collection.
RNA extraction
RNA was extracted from whole blood using the PAXgene™
Blood RNA System Kit employing an amended version of
the manufacturer's guidelines. Briefly, the samples were
removed from -80°C and incubated at room temperature
for 2 hours to ensure complete lysis. Following lysis the
tubes were centrifuged for 10 min at 5,000 × g (Boeco M-
24 centrifuge), the supernatant decanted and 500 µL of
RNase-free water added to the pellet. The tube was vor-
texed to thoroughly re-suspend the pellet, centrifuged for
10 min at 5000 × g and the entire supernatant discarded.
The remaining pelleted lysate was re-suspended in 360 µL
of buffer BR1 by vortexing and the manufacturer's proto-
col was followed from this step.
RNA concentration and analysis
Freshly extracted RNA was measured using a NanoDrop
ND-1000 UV-visible spectrophotometer [Labtech Interna-
Box and whisker plot of relative gene expression in the ICAM-1 and IL-6 genes in survivors (n = 62), non-survivors (n = 25) and controls (n = 16)Figure 3
Box and whisker plot of relative gene expression in the ICAM-1 and IL-6 genes in survivors (n = 62), non-survivors (n = 25) 
and controls (n = 16). The dark line represents the median, and the box represents the interquartile range. The whiskers rep-
resent the range, and outliers are depicted as small circles.
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tion in ng/µL. There is also a quality output, which
provides 260/280 and 260/230 ratios enabling purity esti-
mations. RNA integrity was additionally assessed using
the Agilent 2100 Bioanalyser [Agilent Technologies]. Sam-
ples were loaded on to either the Eukaryote total RNA
nano chip or the Eukaryote total RNA pico chip.
Assessment of RNA integrity by qPCR
To evaluate the utility of the RNA achieved by this method
we then carried out RT qPCR analysis on a panel of 10
assays on a total of 8 housekeeper genes as detailed in
Table 1. As a further quality control (QC) measure with
enhanced sensitivity, we developed assays to 3 regions of
GAPDH; termed 3', mid and 5'. By using oligo dT for the
priming step during reverse transcription it is possible to
use the presence of the mid and 5' assays for GAPDH to
confirm that full length transcripts are present. RNA (1
µg) was reverse transcribed using SuperScript II™ reverse
transcriptase (Invitrogen Ltd, Paisley, UK) following the
manufacturer's guidelines, with oligo dT12–18 used for
priming. RT qPCR assays were designed using locked
nucleic acid analogues (LNA) of fluorescence resonance
energy transfer hydrolysis probes [19] employed in the
Human Universal Probe Library system (Roche, Switzer-
land), with amplification primers obtained from MWG
(Edersberg, Germany). Experiments were performed on
an ABI 7900 Real-Time Sequence Detection System in 384
well format, using an EpMotion 5070 robot (Eppendorf,
Germany) for plate set up.
Reverse transcription
RNA was reverse transcribed using SuperScript II™ RNase
H reverse transcriptase (Invitrogen Ltd, Paisley, UK) fol-
lowing the manufacturer's guidelines. Reactions were
primed using 1 µL oligo (dT)12–18 (500 µg/mL) and took
place in the presence of RNaseOUT™ (all reagents were
from Invitrogen Ltd, Paisley, UK)
Real-time quantitative PCR measurement of ICAM and IL-
6 genes
The Human Universal Probe Library system [19] (Roche,
Switzerland) employing proprietary LNA analogues was
used for RT qPCR to measure expression levels in genes of
interest. Using the Roche Online Assay Design Centre,
specific primers and an associated probe were selected for
the ICAM transcript. To compensate for variations in cell
number, RNA isolation, reverse transcription and PCR
amplification efficiency, three endogenous 'house-keep-
ing' transcripts were chosen using the GeNORM algo-
rithm [20]. Briefly, the cases and controls were screened
for 8 reference genes, the algorithm works out the stability
of each transcript, and sequentially removes the least sta-
ble transcript until the three most stable transcripts
remain. These were; HPRT1 (Hypoxanthine phosphoribo-
syl transferase 1), YWHAZ (tyrosine 3 monooxygenase)
and GAPDH glyceraldehyde 3 phosphate dehydrogenase.
Table 1: Real time PCR primers and probes
Gene name Accession No. Universal Probe No. Primer Primer sequence
B2M NM_004048.2 42 sense ttctggcctggaggctatc
non-sense tcaggaaatttgactttccattc
Beta Actin NM_001101.2 11 sense attggcaatgagcggttc
non-sense ggatgccacaggactccat
HPRT NM_000194. 73 sense tgaccttgatttattttgcatacc
non-sense cgagcaagacgttcagtcct
L14 BC000606 8 sense tcctcaagtttccgcacagt
non-sense ggctgcccattttgtattga
L32 NM_000994.3 17 sense gaagttcctggtccacaacg
non-sense gcgatctcggcacagtaag
SDHA NM_004168.1 69 sense agaagccctttgaggagca
non-sense cgattacgggtctatattccaga
YWHAZ NM_003406.2 9 sense cgttacttggctgaggttgc
non-sense tgcttgttgtgactgatcgac
GAPDH 3' M33197_3 45 sense acacccactcctccaccttt
non-sense tgacaaagtggtcgttgagg
GAPDH mid M33197_M 45 sense gggaaactgtggcgtgat
non-sense gatgaccttgcccacagc
GAPDH 5' M33197_5 9 sense ggaagcttgtcatcaatggaa
non-sense ttgattttggagggatctcg
ICAM1 NM_000201 10 sense agcttctcctgctctgcaac
non-sense aatccctctcgtccagtcg
IL-6 NM_000600 40 sense gatgagtacaaaagtcctgatcca
non-sense ctgcagccactggttctgtPage 6 of 8
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µL diluted cDNA, 10 µL 2× qPCR Master Mix with UNG
(Eurogentec Ltd., Southampton, UK), 0.2 µL each primer
(20 µM) (Metabion, Planegg-Martinsried, Germany), 0.2
µL Probe (10 µM) Human Universal Probe Library system
[19] (Roche, Switzerland), and 4.4 µL of water. Samples
were then amplified on an ABI 7700 PRISM SDS, and the
temperature programme resembled 50°C for 2 min, 95°C
for 10 min followed by 40 cycles of 95°C for 15 sec and
60°C for 1 min. The amounts of target genes expressed in
a sample are normalized to the average of the three endog-
enous controls. This is given by ∆CT, where ∆CT is deter-
mined by subtracting the average endogenous gene CT
value from the average target gene CT value. [CT target gene
- CT average (endogenous gene)]. The calculation of ∆∆CT
involves subtraction of ∆CT value for the controls from the∆CT value for the cases [∆CT target gene(case) - ∆CT target
gene(control)]. 2-∆∆Ct is the relative expression of the target
gene in cases compared to controls.
Statistics
For comparisons (between survivors and non-survivors
with invasive pneumococcal disease, and healthy afebrile
controls), the Mann Whitney test was used to compare
two groups and Kruskal Wallis to compare three groups.
Values of p < 0.005 were considered statistically signifi-
cant. SPSS statistical software version 14 (SPSS, Chicago,
IL) was used for all statistical analyses.
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